Prenatal Screening’s Unexpected Role in Detecting Maternal Cancers

Recent research by the National Human Genome Research Institute (NHGRI) has revealed that non-invasive prenatal testing (NIPT), commonly used to detect fetal chromosomal abnormalities, can also identify undiagnosed cancers in expectant mothers. NIPT analyzes cell-free DNA in the mother’s bloodstream, which includes DNA from both the placenta and potential tumor cells. In a study involving 107 pregnant women with abnormal NIPT results, nearly half were diagnosed with cancer, predominantly lymphoma, colon, and breast cancers. The study advocates for whole-body MRI as a follow-up diagnostic tool when NIPT results suggest malignancy, as traditional evaluations like physical exams and blood tests may not detect these cancers. This finding underscores the importance of comprehensive follow-up for abnormal NIPT results to ensure timely cancer diagnosis and treatment.

At InGeNA, we recognize the transformative role genomics can play in improving health outcomes at such a critical time. The ability of NIPT to detect maternal cancers provides parents with knowledge that not only reduces stress but also significantly mitigates risks. Genomics offers a safe, reliable, and powerful approach during pregnancy, enabling timely diagnosis and treatment to safeguard the health of mothers and their growing families.

The implementation of genomics in maternal care is a significant step forward, underscoring its value in both prenatal health and broader healthcare applications.

For a detailed exploration of this study, read the full article on NHGRI’s website.

Stay informed about the latest developments in genomics by following InGeNA for updates on the global genomics industry.